Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud
Abstract Background Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials. Objectives To conduct a meta-analysis with randomized controlled trials of ivermectin for the preventio...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2022-04, Vol.77 (5), p.1413-1416 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1416 |
|---|---|
| container_issue | 5 |
| container_start_page | 1413 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 77 |
| creator | Hill, Andrew Mirchandani, Manya Ellis, Leah Pilkington, Victoria |
| description | Abstract
Background
Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials.
Objectives
To conduct a meta-analysis with randomized controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. The primary outcome was RT–PCR-confirmed COVID-19 infection. The secondary outcome was rate of symptomatic COVID-19 infection.
Methods
We conducted a subgroup analysis based on the quality of randomized controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane risk of bias measures (RoB 2) and additional checks on raw data, where possible.
Results
Four studies were included in the meta-analysis. One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias. Ivermectin did not have a significant effect on preventing RT–PCR-confirmed COVID-19 infection. Ivermectin had a significant effect on preventing symptomatic COVID-19 infection in one trial with some concerns of bias, but this result was based on post hoc analysis of a multi-arm study.
Conclusions
In this meta-analysis, the use of ivermectin was not associated with the prevention of RT–PCR-confirmed or symptomatic COVID-19. The currently available randomized trials evaluating ivermectin for the prevention of COVID-19 are insufficient and of poor quality. |
| doi_str_mv | 10.1093/jac/dkac052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9326581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkac052</oup_id><sourcerecordid>2631864332</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-550141e910e6c00ca94f33c2f7adb842eeb49fd4073edd6b6686a91527150f913</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoMo7rh68i45iSDtVj6n42FBxq-Bhb3oXkM6qexm7em0SfeA_94eZlz04ilQeXjqpV5CXjJ4x8CIi3vnL8IP50HxR2TFpIaGg2GPyQoEqGYtlTgjz2q9BwCtdPuUnAnFDLSCrcjNdo9lh35KA4250OkO6Vhwj8OU8kBzpJvrm-3Hhpn31IVQsNY03NIxTwfC9bRLrlI3BLrDkPwyiMXN4Tl5El1f8cXpPSffP3_6tvnaXF1_2W4-XDVeSD41SgGTDA0D1B7AOyOjEJ7HtQtdKzliJ00MEtYCQ9Cd1q12him-ZgqiYeKcXB6949wtAfwSqrjejiXtXPlls0v2358h3dnbvLdGcK3ag-DNSVDyzxnrZHepeux7N2Ceq-VasFZLIfiCvj2ivuRaC8aHNQzsoQm7NGFPTSz0q7-TPbB_Tr8Ar49Ansf_mn4D_ACSTg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2631864332</pqid></control><display><type>article</type><title>Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Hill, Andrew ; Mirchandani, Manya ; Ellis, Leah ; Pilkington, Victoria</creator><creatorcontrib>Hill, Andrew ; Mirchandani, Manya ; Ellis, Leah ; Pilkington, Victoria</creatorcontrib><description>Abstract
Background
Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials.
Objectives
To conduct a meta-analysis with randomized controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. The primary outcome was RT–PCR-confirmed COVID-19 infection. The secondary outcome was rate of symptomatic COVID-19 infection.
Methods
We conducted a subgroup analysis based on the quality of randomized controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane risk of bias measures (RoB 2) and additional checks on raw data, where possible.
Results
Four studies were included in the meta-analysis. One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias. Ivermectin did not have a significant effect on preventing RT–PCR-confirmed COVID-19 infection. Ivermectin had a significant effect on preventing symptomatic COVID-19 infection in one trial with some concerns of bias, but this result was based on post hoc analysis of a multi-arm study.
Conclusions
In this meta-analysis, the use of ivermectin was not associated with the prevention of RT–PCR-confirmed or symptomatic COVID-19. The currently available randomized trials evaluating ivermectin for the prevention of COVID-19 are insufficient and of poor quality.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkac052</identifier><identifier>PMID: 35190831</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antiparasitic Agents ; COVID-19 - drug therapy ; Editor's Choice ; Fraud ; Humans ; Ivermectin - therapeutic use ; Original Research ; Randomized Controlled Trials as Topic ; Treatment Outcome</subject><ispartof>Journal of antimicrobial chemotherapy, 2022-04, Vol.77 (5), p.1413-1416</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-550141e910e6c00ca94f33c2f7adb842eeb49fd4073edd6b6686a91527150f913</citedby><cites>FETCH-LOGICAL-c342t-550141e910e6c00ca94f33c2f7adb842eeb49fd4073edd6b6686a91527150f913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1583,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35190831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hill, Andrew</creatorcontrib><creatorcontrib>Mirchandani, Manya</creatorcontrib><creatorcontrib>Ellis, Leah</creatorcontrib><creatorcontrib>Pilkington, Victoria</creatorcontrib><title>Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Abstract
Background
Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials.
Objectives
To conduct a meta-analysis with randomized controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. The primary outcome was RT–PCR-confirmed COVID-19 infection. The secondary outcome was rate of symptomatic COVID-19 infection.
Methods
We conducted a subgroup analysis based on the quality of randomized controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane risk of bias measures (RoB 2) and additional checks on raw data, where possible.
Results
Four studies were included in the meta-analysis. One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias. Ivermectin did not have a significant effect on preventing RT–PCR-confirmed COVID-19 infection. Ivermectin had a significant effect on preventing symptomatic COVID-19 infection in one trial with some concerns of bias, but this result was based on post hoc analysis of a multi-arm study.
Conclusions
In this meta-analysis, the use of ivermectin was not associated with the prevention of RT–PCR-confirmed or symptomatic COVID-19. The currently available randomized trials evaluating ivermectin for the prevention of COVID-19 are insufficient and of poor quality.</description><subject>Antiparasitic Agents</subject><subject>COVID-19 - drug therapy</subject><subject>Editor's Choice</subject><subject>Fraud</subject><subject>Humans</subject><subject>Ivermectin - therapeutic use</subject><subject>Original Research</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhoMo7rh68i45iSDtVj6n42FBxq-Bhb3oXkM6qexm7em0SfeA_94eZlz04ilQeXjqpV5CXjJ4x8CIi3vnL8IP50HxR2TFpIaGg2GPyQoEqGYtlTgjz2q9BwCtdPuUnAnFDLSCrcjNdo9lh35KA4250OkO6Vhwj8OU8kBzpJvrm-3Hhpn31IVQsNY03NIxTwfC9bRLrlI3BLrDkPwyiMXN4Tl5El1f8cXpPSffP3_6tvnaXF1_2W4-XDVeSD41SgGTDA0D1B7AOyOjEJ7HtQtdKzliJ00MEtYCQ9Cd1q12him-ZgqiYeKcXB6949wtAfwSqrjejiXtXPlls0v2358h3dnbvLdGcK3ag-DNSVDyzxnrZHepeux7N2Ceq-VasFZLIfiCvj2ivuRaC8aHNQzsoQm7NGFPTSz0q7-TPbB_Tr8Ar49Ansf_mn4D_ACSTg</recordid><startdate>20220427</startdate><enddate>20220427</enddate><creator>Hill, Andrew</creator><creator>Mirchandani, Manya</creator><creator>Ellis, Leah</creator><creator>Pilkington, Victoria</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220427</creationdate><title>Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud</title><author>Hill, Andrew ; Mirchandani, Manya ; Ellis, Leah ; Pilkington, Victoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-550141e910e6c00ca94f33c2f7adb842eeb49fd4073edd6b6686a91527150f913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiparasitic Agents</topic><topic>COVID-19 - drug therapy</topic><topic>Editor's Choice</topic><topic>Fraud</topic><topic>Humans</topic><topic>Ivermectin - therapeutic use</topic><topic>Original Research</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hill, Andrew</creatorcontrib><creatorcontrib>Mirchandani, Manya</creatorcontrib><creatorcontrib>Ellis, Leah</creatorcontrib><creatorcontrib>Pilkington, Victoria</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hill, Andrew</au><au>Mirchandani, Manya</au><au>Ellis, Leah</au><au>Pilkington, Victoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2022-04-27</date><risdate>2022</risdate><volume>77</volume><issue>5</issue><spage>1413</spage><epage>1416</epage><pages>1413-1416</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Abstract
Background
Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials.
Objectives
To conduct a meta-analysis with randomized controlled trials of ivermectin for the prevention of COVID-19, while controlling for the quality of data. The primary outcome was RT–PCR-confirmed COVID-19 infection. The secondary outcome was rate of symptomatic COVID-19 infection.
Methods
We conducted a subgroup analysis based on the quality of randomized controlled trials evaluating ivermectin for the prevention of COVID-19. Quality was assessed using the Cochrane risk of bias measures (RoB 2) and additional checks on raw data, where possible.
Results
Four studies were included in the meta-analysis. One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias. Ivermectin did not have a significant effect on preventing RT–PCR-confirmed COVID-19 infection. Ivermectin had a significant effect on preventing symptomatic COVID-19 infection in one trial with some concerns of bias, but this result was based on post hoc analysis of a multi-arm study.
Conclusions
In this meta-analysis, the use of ivermectin was not associated with the prevention of RT–PCR-confirmed or symptomatic COVID-19. The currently available randomized trials evaluating ivermectin for the prevention of COVID-19 are insufficient and of poor quality.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35190831</pmid><doi>10.1093/jac/dkac052</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2022-04, Vol.77 (5), p.1413-1416 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9326581 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Antiparasitic Agents COVID-19 - drug therapy Editor's Choice Fraud Humans Ivermectin - therapeutic use Original Research Randomized Controlled Trials as Topic Treatment Outcome |
| title | Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ivermectin%20for%20the%20prevention%20of%20COVID-19:%20addressing%20potential%20bias%20and%20medical%20fraud&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Hill,%20Andrew&rft.date=2022-04-27&rft.volume=77&rft.issue=5&rft.spage=1413&rft.epage=1416&rft.pages=1413-1416&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkac052&rft_dat=%3Cproquest_pubme%3E2631864332%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2631864332&rft_id=info:pmid/35190831&rft_oup_id=10.1093/jac/dkac052&rfr_iscdi=true |